Sun Pharma's major shareholders announced Thursday that their council will consider restoring the company's shares next week.
According to analysts, more promoters can announce resellers to boost trust among stockholders and maintain their markets during the panic sale seen in the markets.
"We see the destruction unprecedented in the market. Dalxiisyaashu now will look at ways looga prevent erosion of the property. We can see that many companies announce samples, re-purchase, to the trust shares to protect , "said managing director G Chokkalingam. , Research and Advisory Services.
According to analysts, the promoters and managers of the company are likely not to focus on the tax implications of recession or dividend and focus on significantly reducing market erosion.
Year-to-date, shares of Sun Pharma stock saw a fall of Rs 17.7 per cent. Shares on Thursday touched a 52-week high of Rs 346.65. The share price ended at eight percent lower at Rs 357.
As of December 31, 2019, insiders held a 54.56 percent stake in the company.
According to analysts the case study rating in the United States is still growing at Sun Pharma's share price. However, Securities ICICI said in writing that the reason for the current valuation has negative consequences in the case of valuation and concerns about the slow-moving of the portfolio.